MaxCyte, Inc.

MaxCyte, Inc.

MXCT·NASDAQ

$1.20

-0.63%
HealthcareMedical - Devices

MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.

At a Glance

Live Snapshot
Market Cap$128.55M
EPS-0.4200
P/E Ratio-2.86
Earnings Date08/12/2026

mxct

Operating Cash Flow

Last Annual Value

-34.41M

3-Year CAGR

-33%

5-Year CAGR

-31%

10-Year CAGR

-69%

MaxCyte, Inc.

MaxCyte, Inc. Competitors Analysis of Operating Cash Flow

MXCT · NASDAQ
CompanyOperating Cash Flow
CAGR 3Y
CAGR 5Y
CAGR 10Y
MXCT logo
MaxCyte, Inc.
NASDAQ:MXCT
-34.41M
N/AN/AN/A 
-82.48M
N/AN/AN/A
-4.40M
N/AN/AN/A
-50.88M
N/AN/AN/A
HYPR logo
Hyperfine, Inc.
NASDAQ:HYPR
-27.95M
N/AN/AN/A
-31.06M
N/AN/AN/A
-29.69M
N/AN/AN/A
-18.01M
N/AN/AN/A
OWLT logo
Owlet, Inc.
NYSE:OWLT
-10.80M
N/AN/AN/A
-25.76M
N/AN/AN/A
LNSR logo
LENSAR, Inc.
NASDAQ:LNSR
-14.83M
N/AN/AN/A
MaxCyte, Inc.

MaxCyte, Inc. Fair Value Envelope

MXCT · NASDAQ

Our analysis suggests that MXCT has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.2, this represents a potential HIDDEN relative to our calculated worth for MaxCyte, Inc..

Intrinsic Value
Current Price: $1.2